Prevention of atrial fibrillation
135 results
1 - 100
Prevention of atrial fibrillation - Dronedarone in the prevention of atrial fibrillation - Image
- Angiotensin receptor blockers or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation
- Management of acute atrial fibrillation
- Indications for and implementation of anticoagulant therapy in atrial fibrillation
- Treatment approach for atrial fibrillation: rate control or rhythm control?
ARBs & ACE inhibitors prevent A fib
Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter: Cochrane systematic review- Atrial fibrillation recurrence higher with episodic treatment with amiodarone
- Warfarin therapy
- Warfarin or antiplatelet therapy for stroke prevention in patients with non-valvular atrial fibrillation
- For device-detected atrial fibrillation, anticoagulation decreases stroke risk (NNT = 100), increases major bleeding (NNTH = 62)
- Dronedarone in atrial fibrillation
- Low-dose edoxaban effective for stroke prevention for elderly patients with atrial fibrillation
- Adults with atrial fibrillation who survive ICH and resume DOACs have fewer strokes but more recurrent ICH (PRESTIGE-AF)
- Choice of prophylactic medication for atrial fibrillation - Image
- Antithrombotic agents in primary health care
- NOACs preferred over warfarin for nonvalvular atrial fibrillation in patients also taking low-dose aspirin
- Treatment of atrial flutter
- Heart valve operation: patient follow-up and complications
- Interventions for preventing post‐operative atrial fibrillation in patients undergoing heart surgery
- Warfarin prevents more strokes than clopidorel+ASA in a fib (ACTIVE)
- Warfarin > aspirin in preventing strokes in pts older than 75 with A fib (BAFTA)
- No worsening of post-op atrial arrhythmias with relaxed potassium supplementation following coronary artery bypass grafting (TIGHT K)
- Lenient = strict rate control in prevention of adverse outcomes in AF
- Greater risk of serious bleeding with diltiazem vs metoprolol in adults with atrial fibrillation using apixaban or rivaroxaban
- Oral anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks
- Selecting anticoagulant therapy in atrial fibrillation - Image
- Dabigatran reduces risk of stroke and embolism in patients with AF
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
- Apixaban reduces stroke and embolism more than aspirin in A fib
- Colchicine prevents postpericardiotomy syndrome following cardiac surgery
- Benefits/harms of novel oral anticoagulants similar in general population and the elderly
- Fewer major bleeds with edoxaban than with warfarin, but treatment benefit unclear (ENGAGE-AF)
- Warfarin for preventing stroke in patients with non-valvular atrial fibrillation and no history of cerebral ischaemia
- In adults with atrial fibrillation and acute ischemic strokes, early (within 4 days) and delayed (7-10 days) initiation of DOACs have similar outcomes (OPTIMAS)
- Rivaroxaban + clopidogrel causes somewhat less bleeding than triple therapy in patients with AF undergoing PCI
- Prescription omega-3 fatty acids do not reduce risk of recurrent A fib
- Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack: Cochrane systematic review
- Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack: Cochrane systematic review
- Antiplatelet therapy for patients with non-valvular atrial fibrillation
- Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
- Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks: Cochrane systematic review
- Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks: Cochrane systematic review
- Direct oral anticoagulants
- Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack: Cochrane systematic review
- AHA guideline for secondary stroke prevention
- Electrical cardioversion
- Bleeding risk with warfarin high among elderly, especially older than 80
- Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
- No reduction in stroke recurrence with apixaban vs aspirin in patients with cryptogenic stroke and atrial cardiopathy (ARCADIA)
- Dual therapy with dabigatran and clopidogrel preferred after PCI for patients with AF (RE-DUAL PCI)
- Aortic stenosis
- Factor Xa inhibitors versus vitamin K antagonists for preventing embolism in patients with atrial fibrillation
- Cerebral infarction (ischaemic stroke)
- Direct oral anticoagulants versus vitamin K antangonists in non-valvular atrial fibrillation
- Warfarin superior to antiplatelet treatment for A Fib
- Mitral regurgitation
- Closure vs. medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or TIA
- Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin: Cochrane systematic review
- Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
- Hypertrophic cardiomyopathy
- Dilated cardiomyopathy
- Dabigatran versus vitamin K antagonists in non-valvular atrial fibrillation
- Low-dose aspirin not effective for primary prevention of CV events (again) and increases risk of serious bleeding